Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight loss of up to 20% over 52 weeks in individuals living with obesity or overweight but without type 2 diabetes. For those with diabetes, the average weight loss reached 17%.
Amgen stock slips as obesity drug study disappoints Wall Street
Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly obesity drug MariTide. Despite the medication demonstrating the ability to reduce an individual's body weight by 20%,
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback